Singulair patents expiration

SINGULAIR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007830 ORGANON Granule formation
Oct, 2022

(10 months ago)

Singulair is owned by Organon.

Singulair contains Montelukast Sodium.

Singulair has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Singulair are:

  • US8007830

Singulair was authorised for market use on 26 July, 2002.

Singulair is available in granule;oral dosage forms.

The generics of Singulair are possible to be released after 24 October, 2022.

Drugs and Companies using MONTELUKAST SODIUM ingredient

Market Authorisation Date: 26 July, 2002

Treatment: NA


How can I launch a generic of SINGULAIR before it's drug patent expiration?
More Information on Dosage

SINGULAIR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic